View More Recent Stories
-
Celldex (CLDX) Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
-
Celldex (CLDX) Tops Q2 EPS by 5c
-
Celldex (CLDX) Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
-
Celldex (CLDX) Initiates Global Phase 3 Program for Barzolvolimab
-
Stifel Starts Celldex Therapeutics (CLDX) at Buy
-
Wolfe Research Starts Celldex Therapeutics (CLDX) at Outperform

